title: Effects of growth hormone plus a hyperproteic diet on methotrexate-induced injury in rat intestines.
abstract: The aim of this study was to determine whether growth hormone treatment reduces injury to the intestinal mucosa induced by methotrexate (MTX). Wistar rats with intestinal injury induced by methotrexate were treated with daily growth hormone, beginning 3 days before MTX treatment until 3 or 4 days after MTX administration. The rats were killed at 3 or 7 days post-MTX administration. The rats were fed with either a normoproteic diet or a hyperproteic diet. Body weight, mortality, bacterial translocation, intestinal morphometry, proliferation and apoptosis and blood somatostatin and IGF-1 were determined. Combined administration of growth hormone and a hyperproteic diet reduces MTX-induced mortality. This effect was accompanied by increased cell proliferation and decreased apoptosis within the crypt. Morphometric data showed complete recovery of the mucosa by day 7 post-MTX administration. These results indicate a synergistic protective action of growth hormone combined with a hyperproteic diet to MTX-induced injury.
authors.affiliation: Experimental Research Service, University Hospital La Paz, Castellana, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Ortega
authors.forename: I A
authors.initials: IA
authors.lastname: Gomez-de-Segura
authors.forename: I
authors.initials: I
authors.lastname: Vázquez
authors.forename: J M
authors.initials: JM
authors.lastname: López
authors.forename: C L
authors.initials: CL
authors.lastname: de Guevara
authors.forename: E
authors.initials: E
authors.lastname: De-Miguel
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001284:Atrophy; D018988:Bacterial Translocation / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004044:Dietary Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D019382:Human Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007410:Intestinal Diseases / Q000139:chemically induced / Q000517:prevention & control*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D019394:Ki-67 Antigen / Q000032:analysis; D008286:Malabsorption Syndromes / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008727:Methotrexate / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013004:Somatostatin / Q000097:blood; D053561:Somatostatin-28
chemical_list: D004044:Dietary Proteins; D019394:Ki-67 Antigen; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D053561:Somatostatin-28; D008727:Methotrexate